Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
Healthcare
$1.91 +0.88%
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
52W Low $5.34High $18.38
Volume 0.70M
Average 0.62M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$35.80M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$38.51M
FY 2025 · Annual
-61.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.47M) | (11.05M) | (7.71M) | (17.6M) | (52.6M) |
| Depreciation & Amortization | 108.98K | 113.33K | 8K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 191K | 1.13M | 0 |
| Change in Working Capital | (610.09K) | (1.45M) | 1.58M | 1.64M | (2.36M) |
| Accounts Receivables | (22.5K) | 0 | (306K) | 58K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | (344.95K) | 1.65M | 1.06M | 2.88M |
| Other Working Capital | (587.59K) | (1.1M) | 237K | 523K | (5.25M) |
| Other Non-Cash Items | 22.12M | 366.86K | 25K | 23K | 19.16M |
| Operating Cash Flow | (10.86M) | (12.01M) | (5.9M) | (14.81M) | (35.8M) |
| Capital Expenditures | (5.25K) | (2.33K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (345.54K) | 0 | 0 | 0 | 0 |
| Sales of Investments | 803.4K | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 3K | 0 | 0 |
| Investing Cash Flow | 452.61K | (2.32K) | 3K | 0 | 0 |
| Debt Repayment | 0 | 624.3K | (624K) | (501K) | 0 |
| Common Stock Issued | 9.19M | 7.93M | 14.19M | 100.37M | 38.51M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 544.65K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 9.74M | 8.55M | 13.57M | 99.87M | 38.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (666.32K) | (3.46M) | 7.67M | 85.06M | 2.71M |
| Free Cash Flow | (10.86M) | (12.02M) | (5.9M) | (14.81M) | (35.8M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$52.6M
+ D&A$0
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$2.4M
+ Other Non-Cash$19.2M
= Operating Cash Flow-$35.8M
- Capex$0
= Free Cash Flow-$35.8M
Analysis
FY2025 free cash flow is -$35.8M. FCF conversion is 68.1% of net income. Operating cash flow was -$35.8M, with capex of $0. The largest bridge item is Other Non-Cash at $19.2M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 15, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 15, 2026 | |
| SC 13G/A | SC 13G/A filing | Sep 11, 2026 | |
| 8-K | Current report | Sep 9, 2026 |
Does TENX generate free cash flow?
Tenax Therapeutics, Inc. (TENX) generated -$35.80M of free cash flow in fiscal 2025.
How much operating cash flow does TENX produce?
Operating cash flow was -$35.80M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.